Condition: Low Grade Serous Ovarian Carcinoma · Adult Type Granulosa Cell Tumor · Sponsor: Universitaire Ziekenhuizen KU Leuven
The purpose of this study is to assess the efficacy and safety of abemaciclib and letrozole for treatment of estrogen receptor-positive rare ovarian cancer.
This description comes directly from the study's public registry record.
Els Van Nieuwenhuysen, MD PhD · +3216342531 · els.vannieuwenhuysen@uzleuven.be
Tine Ottenbourgs · +3216348131 · tine.ottenbourgs@uzleuven.be
Always discuss trial participation with your own doctor first.
| CHU de Liège | Liège, Liège, Belgium | Recruiting |
| UZ Gent | Ghent, Oost-Vlaanderen, Belgium | Recruiting |
| UZ Leuven | Leuven, Vlaams-Brabant, Belgium | Recruiting |
| Institut De Cancerologie Strasbourg Europe | Strasbourg, Bas-Rhin, France | Recruiting |
| Institut Bergonie | Bordeaux, Gironde, France | Recruiting |
| Institut Universitaire Du Cancer Toulouse-Oncopole | Toulouse, Haute-Garonne, France | Recruiting |
| Institut De Cancerologie De L'Ouest | Saint-Herblain, Loire-Atlantique, France | Recruiting |
| Centre Leon Berard | Lyon, Métropole de Lyon, France | Recruiting |
| Groupe Hospitalier Diaconesses Croix Saint Simon | Paris, Île-de-France Region, France | Recruiting |
| University Medical Center Groningen | Groningen, Provincie Groningen, Netherlands | Not Yet Recruiting |
| Erasmus Medical Center Rotterdam | Rotterdam, South Holland, Netherlands | Recruiting |
| University Medical Center Utrecht | Utrecht, Utrecht, Netherlands | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05872204